Patient and physician perceptions of disease management in Parkinson’s disease: results from a US-based multicenter survey

References

• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. doi: 10.1016/S0140-6736(14)61393-325904081
   PubMed Web of Science ®Google Scholar
• Racette BA, Willis AW. Time to change the blind men and the elephant approach to Parkinson disease? Neurology. 2015;85(2):2015190–2015196. doi:10.1212/WNL.0000000000001739
   Web of Science ®Google Scholar
• Lim SY, Tan AH, Fox SH, Evans AH, Low SH. Integrating patient concerns into Parkinson’s disease management. Curr Neurol Neurosci Rep. 2017;17(1):3. doi:10.1007/s11910-017-0717-228102483
   PubMed Web of Science ®Google Scholar
• Groenewegen A, Tofighy A, Ryvlin P, Steinhoff BJ, Dedeken P. Measures for improving treatment outcomes for patients with epilepsy – results from a large multinational patient-physician survey. Epilepsy Behav. 2014;34:58–67. doi:10.1016/j.yebeh.2014.02.03324704566
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25(11):1646–1651. doi:10.1002/mds.2313520629164
   PubMed Web of Science ®Google Scholar
• Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(10):1112–1115. doi:10.1136/jnnp.2009.17328620667858
   PubMed Web of Science ®Google Scholar
• Breen KC, Drutyte G. Non-motor symptoms of Parkinson’s disease: the patient’s perspective. J Neural Transm. 2013;120(4):531–535. doi:10.1007/s00702-012-0928-223224635
   PubMed Web of Science ®Google Scholar
• Weermink MG, van Til JA, van Vugt JP, Movig KL, Groothuis-Oudshoorn CG, IJzerman MJ. Involving patients in weighting benefits and harms of treatment in Parkinson’s disease. PLoS One. 2016;11(8):e0160771. doi:10.1371/journal.pone.016077127575744
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Brown RG, et al. Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD). Health Qual Life Outcomes. 2014;12:11. doi:10.1186/1477-7525-12-1124460704
   PubMed Web of Science ®Google Scholar
• Wüllner U, Fuchs G, Rekatat N, Randerath O, Kassubek J. Requirements for Parkinson’s disease pharmacotherapy from the patients’ perspective: a questionnaire-based survey. Curr Med Res Opin. 2012;28(7):1239–1246. doi:10.1185/03007995.2012.70210122686959
   PubMed Web of Science ®Google Scholar
• Mathers J, Rick C, Jenkinson C, et al. Patients’ experiences of deep brain stimulation for Parkinson’s disease: a qualitative systematic review and synthesis. BMJ Open. 2016;6(6):e011525. doi:10.1136/bmjopen-2016-011525
   PubMed Web of Science ®Google Scholar
• Schrag A, Khan K, Hotham S, Merritt R, Rascol O, Graham L. Experience of care for Parkinson’s disease in European countries: a survey by the European Parkinson’s Disease Association. Eur J Neurol. 2018;25(12):1410-e120. doi:10.1111/ene.13738
   Web of Science ®Google Scholar
• Maffoni M, Giardini A, Pierobon A, Ferrazzoli D, Frazzitta G. Stigma experienced by Parkinson’s disease patients: a descriptive review of qualitative studies. Parkinsons Dis. 2017;2017:7203259. doi:10.1155/2017/720325928243481
   PubMed Web of Science ®Google Scholar
• Fargal M, Grobe B, Oesterle E, Hastedt C, Rupp M. Treatment of Parkinson’s disease: a survey of patients and neurologists. Clin Drug Investig. 2007;27(3):207–218. doi:10.2165/00044011-200727030-00004
   Web of Science ®Google Scholar
• Tinazzi M, Abbruzzese G, Antonini A, et al. Reasons driving treatment modification in Parkinson’s disease: results from the cross-sectional phase of the REASON study. Parkinsonism Relat Disord. 2013;19(12):1130–1135. doi:10.1016/j.parkreldis.2013.08.00623993249
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Barone P, Ceravolo R, et al. Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. Neurol Sci. 2015;36(6):935–943. doi:10.1007/s10072-014-2060-625564417
   PubMed Web of Science ®Google Scholar
• Mammen JR, Elson MJ, Java JJ, et al. Patient and physician perceptions of virtual visits for Parkinson’s disease: a qualitative study. Telemed J E Health. 2018;24(4):255–267. doi:10.1089/tmj.2017.011928787250
   PubMed Web of Science ®Google Scholar
• Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195–202. doi:10.1002/mds.2566424123307
   PubMed Web of Science ®Google Scholar
• Qin Z, Zhang L, Sun F, et al; Chinese Parkinson Study Group. Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord. 2009;15(10):767–771. doi:10.1016/j.parkreldis.2009.05.01119553154
   PubMed Web of Science ®Google Scholar
• Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M; PROMS-PD Study Group. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov Disord. 2012;27(2):236–241. doi:10.1002/mds.2396121954027
   PubMed Web of Science ®Google Scholar
• Jost WH, Bausch J. Patients’ perspective on current treatment options for Parkinson’s disease. Basal Ganglia. 2017;9:7–11. doi:10.1016/j.baga.2017.05.001
   Web of Science ®Google Scholar
• Malek N, Grosset DG. Medication adherence in patients with Parkinson’s disease. CNS Drugs. 2015;29(1):47–53. doi:10.1007/s40263-014-0220-025503824
   PubMed Web of Science ®Google Scholar
• Fleisher JE, Stern MB. Medication nonadherence in Parkinson’s disease. Curr Neurol Neurosci Rep. 2013;13(10):382. doi:10.1007/s11910-013-0382-z23954970
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P. What is quality of life and how do we measure it? Relevance to Parkinson’s disease and movement disorders. Mov Disord. 2017;32(3):382–392. doi:10.1002/mds.2688527911002
   PubMed Web of Science ®Google Scholar
• Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–248. doi:10.1007/BF022608637613534
   PubMed Web of Science ®Google Scholar
• Mischley LK, Lau RC, Weiss NS. Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s disease (PRO-PD): correlation with quality of life and existing scales of disease severity. NPJ Parkinsons Dis. 2017;3:20. doi:10.1038/s41531-017-0021-528649620
   PubMed Web of Science ®Google Scholar
• Biemans MA, Dekker J, van der Woude LH. The internal consistency and validity of the self-assessment Parkinson’s disease disability scale. Clin Rehabil. 2011;15(2):221–228. doi:10.1191/026921501667641185
   Web of Science ®Google Scholar